Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Afuresertib

Home DrugsAfuresertib

Investigational

Small Molecule

Afuresertib

Unknown Manufacturer

Afuresertib has been used in trials studying the treatment of Cancer and Neoplasms, Haematologic.

Generate AI report

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Overview

Afuresertib has been used in trials studying the treatment of Cancer and Neoplasms, Haematologic.

Technical identifiers

Chemical Formula: C₁₈H₁₇Cl₂FN₄OS
CAS Number: 1047644-62-1
UNII ID: 8739X25QI3

Patents

One entry per invention. Patent families filed in the US, EP, WO and CN offices.

Pharmaceutical combination comprising (a) alpha-isoform specific PI3K inhibitor alpelisib and (b) AKT inhibitor, preferably MK-2206, afuresertib or uprosertib and application in treatment/prevention thereof
Applicant: NOVARTIS AGPriority: 2015
CN
METHOD OF TREATING CANCER
Applicant: LAEKNA LTDPriority: 2019
CN
EP
US
WO
5 publications
COMBINATION TREATMENT FOR CANCER
Applicant: LAEKNA LTDPriority: 2022
US
福瑞塞替的制备方法
Applicant: 上海鲲博玖瑞医药科技发展有限公司Priority: 2020
CN
一种福瑞塞替的制备方法
Applicant: 济南健丰化工有限公司Priority: 2020
CN